SGMO.OOTC
- Sangamo Therapeutics, Inc.
报价延迟最少15分钟:2026/05/17 11:35 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.135 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.44/0.39
|
|
企业价值
56.13M
|
| 资产负债 |
|
每股账面净值
-0.03
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
--
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||
|
||||||||||||||||
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its neurology development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases and development of novel engineered adeno-associated virus, or AAV, capsids to deliver its therapies to the intended neurological targets. The group's pipeline products are Small Fiber Neuropathy, Prion Disease, Tauopathies, ALS/FTD, Huntington's Disease, Fabry Disease, and Hemophilia A. |
